[Association of PPARgamma2 Pro12Ala polymorphism and cognitive dysfunction in hypertension patients]
Yong Peng1, Xiao-jia Luo, Xiao-ping Chen
1Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective:
To study the relationship between PPARgamma2 Pro12Ala polymorphism and cognitive function in patients with primary hypertension.
Methods:
This study enrolled 502 hypertensive patients of Chinese Han population from Jan 2008 to Feb 2009 in West China Hospital of Sichuan University. We collected the general data and applied the mini mental state examination (MMSE) to test the cognitive function and computed score. Total cholesterol (TC), triglyeride (TG), fasting plasma glucose (FPG) and postprandial blood sugar (PPBS), fasting insulin (FINS) and postprandial plasma insulin (PINS) were measured. PCR-RELP method was used to analysis the PPARgamma2 Pro12Ala gene polymorphism.
Results:
Pro12Pro genotype was present in 88.6% of the patients and Prol2Ala genotype was present in 11.4% of the population. Allele frequencies were 94.3% for Pro allele and 5.7% for Ala allele. In cognitive normal group, the frequencies of PP and PA genotype were 328 (87.2%) and 48 (12.8%), while the frequencies of PP and PA genotypes in the cognitive dysfunction group were 126 (92.9%), 9 (7.1%) respectively. Analyzed by chi2 test, both the genotype frequency and the allele frequency of PPARy2 Pro12Ala polymorphism did not display statistical variability between the cognitive normal group and the cognitive dysfunction group, even eliminating the influence of age and sexuality.
Conclusion:
Pro12Ala polymorphism in PPARgamma2 with primary hypertension may not associate with cognitive impairment.
Related Concept Videos
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Hypertension and Regulation of Blood Pressure
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Alzheimer Disease l: Introduction
